- Total collaboration revenue for the second quarter of 2013 was approximately $0.3 million compared with $1.9 million for the second quarter of 2012. The decrease was due to revenue recognized during the second quarter of 2012 related to milestones achieved under our collaboration agreement with OSI, as well as research funding under our collaboration agreement with Centocor, that did not recur during the second quarter of 2013. Revenue during the second quarter of 2013 was related to amortization of amounts previously deferred related to our collaboration agreements with Biogen and Astellas.
- Research and development (R&D) expense for the second quarter of 2013 was $16.2 million compared with $21.5 million for the second quarter of 2012. The decrease in R&D expense was primarily due to a decrease in personnel-related expenses following our strategic restructuring announced in October 2012, as well as a decrease in clinical trial costs due to a decrease in the number of active patients enrolled in our ficlatuzumab and tivozanib studies.
- General and administrative (G&A) expense for the second quarter of 2013 was $7.3 million compared with $9.2 million for the second quarter of 2012. The decrease in G&A expense was primarily due to the reversal of stock-based compensation expense for certain awards that are no longer probable of vesting and a decrease in personnel-related expenses related to our strategic restructuring announced on June 4, 2013.
- Restructuring expense for the three months ended June 30, 2013 was $7.9 million, with no corresponding expense for the three months ending June 30, 2012. The restructuring expense primarily consisted of employee severance and related benefits incurred in connection with our strategic restructuring announced on June 4, 2013, extending the company’s cash runway beyond certain potential clinical milestones.
- Net loss for the second quarter of 2013 was $31.9 million, or basic and diluted net loss per share of $0.62, compared with a net loss of $29.5 million, or basic and diluted net loss per share of $0.68 for the second quarter of 2012.
- AVEO ended the second quarter of 2013 with cash, cash equivalents and marketable securities of $156.2 million.
Key Recent Development
- Announced Strategic Restructuring: In connection with the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on June 10, 2013 informing us that the FDA will not approve in its present form our New Drug Application for tivozanib, our lead product candidate, for the treatment of patients with advanced renal cell carcinoma (RCC) and our subsequent decision not to pursue tivozanib development in RCC, we recently announced a strategic restructuring, pursuant to which we are eliminating approximately 140 positions across the organization. This strategic restructuring will refocus our efforts on the on-going clinical development of tivozanib in colorectal and breast cancer and on the advancement of other key pipeline and preclinical assets.
- Canaccord Genuity 33rd Annual Growth Conference, August 14-15, 2013 in Boston
|AVEO Pharmaceuticals, Inc.|
|Condensed Consolidated Statements of Operations|
|(In thousands, except per share amounts)|
|For the Three Months||For the Six Months|
|Ended June 30,||Ended June 30,|
|Research and development||16,203||21,450||37,165||46,226|
|General and administrative||7,324||9,186||19,773||18,169|
|Loss from operations||(31,072||)||(28,759||)||(64,227||)||(61,658||)|
|Other income and expense:|
|Other income (expense), net||(51||)||(66||)||(152||)||233|
|Other expense, net||(841||)||(787||)||(1,771||)||(1,134||)|
|Net loss per share - basic and diluted||$||(0.62||)||$||(0.68||)||$||(1.31||)||$||(1.45||)|
|Weighted average number of common shares outstanding||51,312||43,322||50,351||43,288|
|AVEO Pharmaceuticals, Inc.|
|Condensed Consolidated Balance Sheets|
|(In thousands, except par value amounts)|
|June 30,||December 31,|
|Cash, cash equivalents and marketable securities||$||156,170||$||160,602|
|Prepaid expenses and other current assets||9,217||9,430|
|Property and equipment, net||13,238||12,867|
|Liabilities and stockholders’ equity|
|Accounts payable and accrued expenses||$||21,544||$||30,171|
|Total loans payable||23,893||26,037|
|Total deferred revenue||19,038||19,685|
|Total deferred rent||15,791||11,400|
|Total liabilities and stockholders’ equity||$||190,410||$||207,469|